Novo Nordisk's (NVO) U.S.-listed shares are surging 9% Friday morning after the Danish drugmaker reported early stage results for its amycretin weight-loss drug.
The maker of Ozempic and Wegovy said that its Phase 1b/2a clinical trial showed people achieved weight loss from a mean baseline body weight of 92.7 kg (202.8 pounds) in three different maintenance doses, while those treated with placebo gained weight. In the highest dosage, 20mg, participants lost 22% of body weight after 36 weeks, while people treated with placebo gained 2% body weight.
At a dosage of 1.25mg over 20 weeks, people treated with amycretin lost 9.7% of their body weight, while those on placebo gained 1.9%. People given a dosage of 5mg over 28 weeks lost 16.2%, while those on placebo gained 2.3%.
Executive vice president for development Martin Lange said Novo Nordisk was "very encouraged" by the results. The firm said it now plans "further clinical development of amycretin in adults with overweight or obesity."
Novo Nordisk's U.S.-listed shares had been trending lower since September, plunging 18% one day last month after trial results for its weight-loss drug CagriSema disappointed.
Shares of Novo Nordisk, which is a leader in the weight-loss drug market with Mounjaro and Zepbound maker Eli Lilly (LLY), had fallen about 23% in the past 12 months entering Friday. Eli Lilly shares slipped 1% soon after the bell but are up about 20% over the last year.
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。